Compare GMAB & HII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GMAB | HII |
|---|---|---|
| Founded | 1999 | 1886 |
| Country | Denmark | United States |
| Employees | 3029 | 44000 |
| Industry | Biotechnology: Pharmaceutical Preparations | Marine Transportation |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.9B | 15.5B |
| IPO Year | N/A | 2010 |
| Metric | GMAB | HII |
|---|---|---|
| Price | $26.56 | $359.23 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 6 |
| Target Price | $39.56 | ★ $411.33 |
| AVG Volume (30 Days) | ★ 1.5M | 358.1K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 1.52% |
| EPS Growth | N/A | ★ 10.24 |
| EPS | N/A | ★ 15.39 |
| Revenue | N/A | ★ $12,484,000,000.00 |
| Revenue This Year | $17.85 | $4.82 |
| Revenue Next Year | $16.04 | $6.28 |
| P/E Ratio | ★ $1.90 | $23.50 |
| Revenue Growth | N/A | ★ 8.23 |
| 52 Week Low | $18.89 | $215.28 |
| 52 Week High | $35.43 | $460.00 |
| Indicator | GMAB | HII |
|---|---|---|
| Relative Strength Index (RSI) | 42.27 | 33.01 |
| Support Level | $24.95 | $351.63 |
| Resistance Level | $29.64 | $360.20 |
| Average True Range (ATR) | 0.54 | 10.92 |
| MACD | -0.18 | -2.41 |
| Stochastic Oscillator | 21.29 | 15.57 |
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
Huntington Ingalls Industries is the largest independent military shipbuilder in the US, spun out from Northrop Grumman in 2011. It operates three segments, two of which are storied shipyards: Ingalls produces non-nuclear-powered ships including amphibious landing ships and Arleigh Burke-class destroyers, while Newport News produces nuclear-powered ships as the only producer of Gerald Ford-class aircraft carriers and a major subcontractor on Virginia- and Columbia-class nuclear submarines. HII shares production of destroyers and nuclear submarines with General Dynamics' Bath Iron Works and Electric Boat shipyards, respectively. The company's mission technologies segment produces uncrewed sea vessels and provides a range of IT and other services to US government agencies.